KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opko Health (OPK) Deferred Taxes (2016 - 2025)

Opko Health (OPK) has disclosed Deferred Taxes for 14 consecutive years, with $1.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Deferred Taxes fell 86.4% year-over-year to $1.9 million, compared with a TTM value of -$3.0 million through Dec 2025, down 113.78%, and an annual FY2025 reading of -$3.0 million, down 113.78% over the prior year.
  • Deferred Taxes was $1.9 million for Q4 2025 at Opko Health, down from $18.3 million in the prior quarter.
  • Across five years, Deferred Taxes topped out at $18.3 million in Q3 2025 and bottomed at -$39.9 million in Q3 2022.
  • Average Deferred Taxes over 5 years is -$593800.0, with a median of $876500.0 recorded in 2023.
  • The sharpest move saw Deferred Taxes soared 746.27% in 2021, then tumbled 39445.54% in 2022.
  • Year by year, Deferred Taxes stood at $7.8 million in 2021, then increased by 4.52% to $8.1 million in 2022, then plummeted by 188.05% to -$7.2 million in 2023, then surged by 293.28% to $13.8 million in 2024, then crashed by 86.4% to $1.9 million in 2025.
  • Business Quant data shows Deferred Taxes for OPK at $1.9 million in Q4 2025, $18.3 million in Q3 2025, and -$15.7 million in Q2 2025.